AR084234A1 - Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) - Google Patents
Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)Info
- Publication number
- AR084234A1 AR084234A1 ARP110104621A ARP110104621A AR084234A1 AR 084234 A1 AR084234 A1 AR 084234A1 AR P110104621 A ARP110104621 A AR P110104621A AR P110104621 A ARP110104621 A AR P110104621A AR 084234 A1 AR084234 A1 AR 084234A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- interleuquine
- antagonists
- predictive
- treat arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42252110P | 2010-12-13 | 2010-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084234A1 true AR084234A1 (es) | 2013-05-02 |
Family
ID=45390221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104621A AR084234A1 (es) | 2010-12-13 | 2011-12-12 | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR084234A1 (zh) |
TW (1) | TW201307845A (zh) |
WO (1) | WO2012082573A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
KR20180129991A (ko) * | 2010-11-05 | 2018-12-05 | 노파르티스 아게 | Il-17 길항제를 사용한 류마티스성 관절염의 치료 방법 |
KR20140097178A (ko) * | 2011-11-21 | 2014-08-06 | 노파르티스 아게 | IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법 |
US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
TWI713436B (zh) | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | 用結合群落刺激因子1受體(csf1r)之抗體治療病狀之方法 |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
EA037561B1 (ru) | 2014-06-23 | 2021-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
WO2016038538A1 (en) * | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
DK3212670T3 (da) | 2014-10-29 | 2021-03-22 | Five Prime Therapeutics Inc | Kombinationsterapi mod cancer |
AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
EP3237447B1 (en) | 2014-12-22 | 2020-12-02 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
US11421034B2 (en) | 2017-09-13 | 2022-08-23 | Five Prime Therapeutics, Inc. | Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974701B2 (en) | 2003-03-21 | 2005-12-13 | Hemovations, Llc | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
WO2007117749A2 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies fpr treating cancer |
CN102617735B (zh) * | 2008-09-29 | 2015-09-09 | 罗氏格黎卡特股份公司 | 针对人il17的抗体及其应用 |
-
2011
- 2011-12-12 AR ARP110104621A patent/AR084234A1/es not_active Application Discontinuation
- 2011-12-12 WO PCT/US2011/064307 patent/WO2012082573A1/en active Application Filing
- 2011-12-12 TW TW100145816A patent/TW201307845A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW201307845A (zh) | 2013-02-16 |
WO2012082573A1 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084234A1 (es) | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) | |
CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
EA201400254A1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
CL2013001213A1 (es) | Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide. | |
EA201300978A1 (ru) | Антитела к сеа | |
UA115034C2 (uk) | Імунокон'югат для застосування в лікуванні раку або запального порушення | |
MY163539A (en) | Antibody fc variants | |
AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
MX2017003565A (es) | Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes. | |
BR112012006035A2 (pt) | epratuzumab para uso no tratamento de uma doença autoimune ou inflamatória, e, kit | |
MX2020000342A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos. | |
MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
MX347020B (es) | Anticuerpo contra el csf-1r. | |
CR20130593A (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
MX2013009679A (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
AR061568A1 (es) | Compuestos | |
EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
MX2014006158A (es) | Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa. | |
EP2542581A4 (en) | SPECIFIC APOLIPOPROTEIN ANTIBODY AND METHODS OF USING SAME | |
TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
CL2012002081A1 (es) | Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria. | |
BR112013032871A8 (pt) | Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 | |
CR20110559A (es) | Anticuerpos específicos para cadherina-17 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |